CASI Pharmaceuticals, Inc. (CASI)

CASI Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	10.9	13.47	17.08	47.11	38.7	57.06
Short-Term Investments	1.8	2.62	13.69	4.23	9.87	9.31
Cash & Short-Term Investments	12.7	16.09	30.77	51.34	48.57	66.37
Cash Growth	-35.42%	-47.70%	-40.06%	5.69%	-26.82%	22.36%
Accounts Receivable	7.6	15.35	9.55	12.97	9.8	4.65
Other Receivables	-	-	0.59	-	-	-
Receivables	7.6	15.35	10.14	12.97	9.8	4.65
Inventory	4.15	5.25	15.88	6.14	1.91	1.36
Prepaid Expenses	2.71	2.89	2.56	2.98	1.69	1.65
Total Current Assets	27.16	39.58	59.34	73.42	61.97	74.03
Property, Plant & Equipment	10.92	11.36	11.63	13.23	21.82	10.76
Long-Term Investments	1.91	1.91	1.69	7.46	40.13	29.44
Other Intangible Assets	0.23	0.24	1.84	1.06	12.2	13.21
Other Long-Term Assets	0.59	0.59	0.77	1.06	2.18	0.3
Total Assets	40.82	53.67	75.27	96.23	138.3	127.73
Accounts Payable	1.2	2.72	4.44	3.29	2.22	3.26
Accrued Expenses	14.03	8.47	7.15	7.64	6.04	1.97
Short-Term Debt	-	-	-	-	-	1.29
Current Portion of Long-Term Debt	18.49	18.39	-	-	-	-
Current Portion of Leases	-	1.22	0.73	0.87	1.06	0.94
Current Income Taxes Payable	-	-	-	1.9	-	-
Current Unearned Revenue	-	2.47	2.54	2.62	0.06	-
Other Current Liabilities	-	3.18	1.87	0.69	3.81	0.52
Total Current Liabilities	33.71	36.45	16.73	17.01	13.19	7.98
Long-Term Debt	-	-	18.9	-	-	-
Long-Term Leases	-	2.54	1.62	0.48	1.11	0.97
Long-Term Unearned Revenue	-	-	-	-	2.83	2.35
Other Long-Term Liabilities	15.18	12.84	13.87	11.82	13.22	12.87
Total Liabilities	48.89	51.82	51.1	29.3	30.34	24.16
Common Stock	0	0	0	0	0	1.24
Additional Paid-In Capital	714.59	713.3	695.79	691.77	696.22	658.25
Retained Earnings	-710.83	-700.08	-660.82	-637.16	-605.64	-570.5
Treasury Stock	-9.6	-9.6	-9.6	-9.33	-8.03	-8.03
Comprehensive Income & Other	-2.23	-1.77	-1.2	-0.7	1.95	0.59
Total Common Equity	-8.07	1.85	24.17	44.57	84.5	81.54
Minority Interest	-	-	-	22.36	23.46	22.03
Shareholders' Equity	-8.07	1.85	24.17	66.93	107.96	103.57
Total Liabilities & Equity	40.82	53.67	75.27	96.23	138.3	127.73
Total Debt	18.49	22.14	21.24	1.34	2.17	3.2
Net Cash (Debt)	-5.79	-6.05	9.53	49.99	46.41	63.18
Net Cash Growth	-	-	-80.94%	7.73%	-26.55%	21.39%
Net Cash Per Share	-0.37	-0.39	0.71	3.66	3.41	5.72
Filing Date Shares Outstanding	5.49	15.49	12.99	13.32	13.66	13.98
Total Common Shares Outstanding	5.49	15.49	13.38	13.46	13.98	12.39
Working Capital	-6.55	3.12	42.62	56.42	48.78	66.05
Book Value Per Share	-1.47	0.12	1.81	3.31	6.04	6.58
Tangible Book Value	-8.3	1.61	22.33	43.51	72.3	68.33
Tangible Book Value Per Share	-1.51	0.10	1.67	3.23	5.17	5.51
Machinery	-	6.58	6.68	1.24	1.73	1.62
Construction In Progress	-	-	0.02	5.73	12.1	1.19
Leasehold Improvements	-	7	7.19	7.16	1.13	0.99

Updated Nov 15, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q